Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parathyroid Allotransplant (University of California, San Francisco)
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- Cell Therapies
- Administration
- Intramuscular
01
Overview
Parathyroid Allotransplant is an investigational biological therapy being developed by Dr. Peter Stock at the University of California, San Francisco (UCSF) for the treatment of hypoparathyroidism. The intervention involves the transplantation of parathyroid tissue harvested from deceased (cadaveric) donors into the brachioradialis muscle of the patient's forearm. The primary therapeutic objective is to establish a functional graft capable of endogenous parathyroid hormone (PTH) production, thereby normalizing serum calcium and phosphorus levels and reducing the patient's dependence on exogenous calcium and vitamin D supplements. This clinical program was initiated in part to address the therapeutic gap left by the discontinuation of NATPARA (rhPTH 1-84). It is currently being evaluated in a Phase 1/2 clinical trial known as PATTH (Parathyroid Allotransplant for Treatment of Hypoparathyroidism).
- Other names
- Parathyroid Allotransplant-Peter Stock-hypoparathyroidismCadaveric Parathyroid AllotransplantParathyroid Allotransplantation
Beyond the preview
Go deeper on Parathyroid Allotransplant (University of California, San Francisco).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Parathyroid Allotransplant (University of California, San Francisco).